Identification of substrate-specific inhibitors of cathepsin K through high-throughput screening. Issue 3 (5th February 2019)

• Record Type: Journal Article
• Authors: Law, Simon; Du, Xin; Panwar, Preety; Honson, Nicolette S.; Pfeifer, Tom; Roberge, Michel; Brömme, Dieter
• Is Part Of: Biochemical journal. Volume 476:Issue 3(2019)
• Page Start: 499
• Page End: 512
• Publication Date: 2019-02-05
• Subjects: cathepsin K -- collagen -- exosite inhibitor -- high-throughput screening -- osteoporosis -- protease inhibitor; Biochemistry -- Periodicals; 572
• DOI: 10.1042/BCJ20180851
• Languages: English
• ISSNs: 0264-6021

Abstract

Abstract : Cathepsin K (CatK) is a cysteine protease and drug target for skeletal disorders that is known for its potent collagenase and elastase activity. The formation of oligomeric complexes of CatK in the presence of glycosaminoglycans has been associated with its collagenase activity. Inhibitors that disrupt these complexes can selectively block the collagenase activity without interfering with the other regulatory proteolytic activities of the enzyme. Here, we have developed a fluorescence polarization (FP) assay to screen 4761 compounds for substrate-specific ectosteric collagenase inhibitors of CatK. A total of 38 compounds were identified that block the collagenase activity without interfering with the hydrolysis of active site substrates such as the synthetic peptide substrate, benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin, and gelatin. The identified inhibitors can be divided into two main classes, negatively charged and polyaromatic compounds which suggest the binding to different ectosteric sites. Two of the inhibitors were highly effective in preventing the bone-resorption activity of CatK in osteoclasts. Interestingly, some of the ectosteric inhibitors were capable of differentiating between the collagenase and elastase activity of CatK depending on the ectosteric site utilized by the compound. Owing to their substrate-specific selectivity, ectosteric inhibitors represent a viable alternative to side effect-prone active site-directed inhibitors.